Considering investing in crispr stocks? While the best crispr stocks depend on your portfolio and investment goals, we've identified some crispr stocks that are worth keeping an eye on in the gene editing sector. Keep reading to learn more about crispr stocks and how to start investing.
We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap stocks.
| Best stock | 1-year return | Market cap | Exchange | Volume | Buy on CIBC Investor's Edge |
|---|---|---|---|---|---|
| Crispr Therapeutics (CRSP.US) | 13.08% | $4.8 billion (USD) | NASDAQ | 2,551,900 | Buy now |
| Editas Medicine (EDIT.US) | 84.62% | $240.8 million (USD) | NASDAQ | 1,237,224 | Buy now |
| Regeneron Pharmaceuticals (REGN.US) | 15.57% | $80.2 billion (USD) | NASDAQ | 1,359,900 | Buy now |
| Cellectis (CLLS.US) | 161.07% | $344 million (USD) | NASDAQ | 32,726 | Buy now |
| Beam Therapeutics Inc (BEAM.US) | 8.40% | $2.5 billion (USD) | NASDAQ | 1,295,200 | Buy now |
| Bluebird bio (BLUE.US) | 29.09% | $48.7 million (USD) | NASDAQ | (data unavailable) | Buy now |
| Sangamo Therapeutics (SGMO.US) | -60.08% | $123.3 million (USD) | NASDAQ | 5,885,639 | Buy now |
The gene editing industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering crispr stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.
Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.
A lot of factors go into picking the best crispr stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong crispr stock investment for one person might not be suitable for another.
That said, we rounded up this list of popular crispr stocks in or related to the gene editing industry to help narrow down your options:
Keep in mind that this is not a "best" list or a recommendation. It highlights some crispr stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.
We've outlined detailed company and stock performance details for each crispr stock below. Keep reading to decide if any of these companies are the right investment for you.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology.
| Closing stock price | $46.24 |
|---|---|
| Market Capitalization | $4.8 billion |
| Gross profit (TTM) | $-494,776,000 |
| Revenue (TTM) | $3.5 million |
| Earnings per share (TTM) | -$6.47 |
| 52-week stock price range | $30.04 – $78.48 |
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
| Closing stock price | $2.40 |
|---|---|
| Market Capitalization | $240.8 million |
| Gross profit (TTM) | $-49,433,000 |
| Revenue (TTM) | $40.5 million |
| Earnings per share (TTM) | -$1.80 |
| 52-week stock price range | $0.91 – $4.54 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
| Closing stock price | $732.87 |
|---|---|
| Market Capitalization | $80.2 billion |
| Gross profit (TTM) | $6.4 billion |
| Profit margin | 31.41% |
| Revenue (TTM) | $14.3 billion |
| Earnings per share (TTM) | $41.44 |
| 52-week stock price range | $474.60 – $820.12 |
Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
| Closing stock price | $3.42 |
|---|---|
| Market Capitalization | $344 million |
| Gross profit (TTM) | $79.6 million |
| Profit margin | -84.92% |
| Revenue (TTM) | $79.6 million |
| Earnings per share (TTM) | -$0.67 |
| 52-week stock price range | $1.10 – $5.48 |
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a.
| Closing stock price | $25.17 |
|---|---|
| Market Capitalization | $2.5 billion |
| Gross profit (TTM) | $-269,875,008 |
| Profit margin | -57.24% |
| Revenue (TTM) | $139.7 million |
| Earnings per share (TTM) | -$0.81 |
| 52-week stock price range | $13.53 – $36.44 |
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
| Closing stock price | $4.97 |
|---|---|
| Market Capitalization | $48.7 million |
| Gross profit (TTM) | $28.2 million |
| Profit margin | -192.39% |
| Revenue (TTM) | $103.9 million |
| Earnings per share (TTM) | -$20.59 |
| 52-week stock price range | $3.20 – $5.42 |
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A.
| Closing stock price | $0.34 |
|---|---|
| Market Capitalization | $123.3 million |
| Gross profit (TTM) | $-72,032,000 |
| Revenue (TTM) | $32.9 million |
| Earnings per share (TTM) | -$0.45 |
| 52-week stock price range | $0.32 – $0.93 |
Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.
We break down which companies hold Ethereum, why they’re doing it and what ETH treasuries mean for markets and investors.
Want to invest in the Euro Stoxx 50 in Canada? Explore investment platforms and popular Euro Stoxx 50 index funds.
What are the best stocks for beginners with little money to invest?
Want to dive into investing but don’t have much to spend? Take a look at these types of stocks.
New to Qtrade? Check out available promotions and offer codes on now.
Enjoy perks like free trades and cash back when you open a stock trading account with these online broker promotions.
What’s the best way to invest money in Canada? Find out how to invest money via stocks, bonds, index funds and more.
Want to invest in precious metals companies? We’ve put together a list of platinum stocks you should keep your eye on.
Want to invest in software-as-a-service companies? We’ve put together a list of SaaS stocks you should keep your eye on.
These are the best renewable energy stocks to buy now in Canada.
Whether you’re a new or experienced investor, these are the best stock trading platforms and apps in Canada.
Find out which trading platform might be the best fit for you based on your unique set of investment needs.
Learn which of these popular trading platforms is the best fit for you depending on your unique investment needs.
Find out how to invest in the S&P 500 in Canada—one of the world’s most popular stock indices—to diversify your portfolio.